4th Edition Global Longevity Federation

Arda Therapeutics Secures $43M Series A Financing to Advance Targeted Cell Depletion Therapies

Arda Therapeutics, a pioneer in targeted cell depletion therapies for chronic diseases, today announced the successful completion of a $43 million Series A financing round. The round was led by existing investor Andreessen Horowitz (a16z Bio + Health), with participation from Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV, Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels and ExitFund.Readmore

Promising ‘first’ in Alzheimer’s drug development

For the first time, scientists have developed a drug that works on both major aggregation-promoting ‘hotspots’ of the Tau protein - addressing a critical gap in current treatments.Readmore

SENS Research Foundation and Lifespan.io Announce Intent to Merge, Forming a Novel Longevity Entity

In a groundbreaking announcement set to impact the future of longevity research and outreach, two historic longevity nonprofits – SENS Research Foundation and Lifespan.io (Lifespan Extension Advocacy Foundation) – have unveiled plans to merge, upon completion of regulatory approvals.Readmore

Booster Therapeutics Launches to Pioneer New Class of Proteasome Activator Medicines for the Treatment of a Range of Complex Diseases

Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, launched today with the support of a $15 million financing led by noted life sciences investors Apollo Health Ventures and Novo Holdings. Booster was founded by Dr. Diogo Feleciano, Prof. Dr. Darci Trader, and Apollo Health Ventures, emerging from Apollo's company creation investment strategy. The company is developing small molecule therapeutics that boost the innate activity of proteasomes to restore the body’s ability to remove a wide range of disease-causing proteins.Readmore